Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 2, 2012, Pages

  Chu, Louis M ^a,b   Robich, Michael P ^a,b   Bianchi, Cesario ^a   Feng, Jun ^a   Liu, Yuhong ^a   Xu, Shu Hua ^b   Burgess, Thomas ^a   Sellke, Frank W ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cholesterol; Myocardial ischemia; Perfusion; Prostaglandins

Indexed keywords

CELECOXIB; ENDOTHELIUM DERIVED RELAXING FACTOR; NAPROXEN; SEROTONIN; THROMBOXANE; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY DENSITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HYPERCHOLESTEROLEMIA; LIPID OXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SWINE;

ANIMALS; CYCLOOXYGENASE INHIBITORS; HEART; HYPERCHOLESTEROLEMIA; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NAPROXEN; OXIDATIVE STRESS; PYRAZOLES; SULFONAMIDES; SWINE;

EID: 84855313805     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00146.2011     Document Type: Article

References (28)

1. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355: 885-895, 2006.
2. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Bum J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2: 285-287, 2009.
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343: 1520-1528, 2000.
4. Boodhwani M, Nakai Y, Mieno S, Voisine P, Bianchi C, Araujo EG, Feng J, Michael K, Li J, Sellke FW. Hypercholesterolemia impairs the myocardial angiogenic response in a swine model of chronic ischemia: role of endostatin and oxidative stress. Ann Thorac Surg 81: 634-641, 2006.
5. Boodhwani M, Voisine P, Ruel M, Sodha NR, Feng J, Xu SH, Bianchi C, Sellke FW. Comparison of vascular endothelial growth factor and fibroblast growth factor-2 in a swine model of endothelial dysfunction. Eur J Cardiothorac Surg 33: 645-650, 2008.
6. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771-1781, 2006.
7. Canton M, Menazza S, Sheeran FL, Polverino de Laureto P, Di Lisa F, SP. Oxidation of myofibrillar proteins in human heart failure. J Am Coll Cardiol 57: 300-309, 2011.
8. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107: 405-409, 2003.
9. Cunha NV, de Abreu SB, Panis C, Grassiolli S, Guarnier FA, Cecchini R, Mazzuco TL, Pinge-Filho P,. Martins-Pinge M.C Cox-2 inhibition attenuates cardiovascular and inflammatory aspects in monosodium glutamate-induced obese rats Life Sci 87: 375-381, 2010.
10. Daray FM, Colombo JR, Kibrik JR, Errasti AE, Pelorosso FG, Nowak W, Cracowski JL, Rothlin RP. Involvement of endothelial thromboxane A2 in the vasoconstrictor response induced by 15-E2tisoprostane in isolated human umbilical vein. Naunyn Schmiedebergs Arch Pharmacol 373: 367-375, 2006.
11. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345: 433-442, 2001.
12. Jerez S, Sierra L, Coviello A, de Bruno MP. Endothelial dysfunction and improvement of the angiotensin II-reactivity in hypercholesterolemic rabbits: role of cyclooxygenase metabolites. Eur J Pharmacol 580: 182-189, 2008.
13. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials BMJ 332: 1302-1308, 2006.
14. Kumari B, Kumar A, Dhir A. Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations. Pharmacol Rep 59: 699-707, 2007.
15. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
16. Mathew V, Cannan CR, Miller VM, Barber DA, Hasdai D, Schwartz RS, Holmes DRJ, Lerman A. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation 96: 1930-1936, 1997.
17. Metais C, Bianchi C, Li J, Li J, Simons M, Sellke FW. Serotonininduced human coronary microvascular contraction during acute myocardial ischemia is blocked by COX-2 inhibition. Basic Res Cardiol 96: 59-67, 2001.
18. Pillinger MH, Capodici C, Rosenthal P, Kheterpal N, Hanft S, Philips MR, Weissmann G. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci USA 95: 14540-14545, 1998.
19. Pritchard KA Jr. Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, and Stemerman MB. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion Circ Res 77: 510-518, 1995.
20. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone J Clin Invest 97: 1916-1923, 1996.
21. Robich MP, Chu LM, Burgess TA, Feng J, Bianchi C, Sellke FW. Effects of Selective Cyclooxygenase-2 and Non-Selective COX Inhibition on Myocardial Function and Perfusion. J Cardiovasc Pharmacol, 2010.
22. Robich MP, Chu LM, Feng J, Burgess TA, Laham RJ, Bianchi C, Sellke FW. Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium. J Thorac Cardiovasc Surg 140: 1143-1152, 2010.
23. Roth DM, Maruoka Y, Rogers J, White FC, Longhurst J, Bloor CM. Development of coronary collateral circulation in left circumflex ameroidoccluded swine myocardium. Am J Physiol Heart Circ Physiol 253: H1279-1288, 1987.
24. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
25. Sodha NR, Clements RT, Feng J, Liu Y, Bianchi C, Horvath EM, Szabo C, Sellke FW. The effects of therapeutic sulfide on myocardial apoptosis in response to ischemia-reperfusion injury. Eur J Cardiothorac Surg 33: 906-913, 2008.
26. Warner TD, Mitchell JA. Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic. FASEB J 18: 790-804, 2004.
27. Xavier FE, Blanco-Rivero J, Sastre E, Badimon L, Balfagon G. Simultaneous inhibition of TxA2 and PGI2 synthesis increases NO release in mesenteric resistance arteries from cirrhotic rats. Clin Sci (Lond) 119: 283-292, 2010.
28. Zhu XY, Daghini E, Rodriguez-Porcel M, Chade AR, Napoli C, Lerman A, Lerman LO. Redox-sensitive myocardial remodeling and dysfunction in swine diet-induced experimental hypercholesterolemia. Atherosclerosis 193: 62-69, 2007.